XELODA 500 MG
CAPECITABINE : 500 MG · DIN 02238454 · CHEPLAPHARM ARZNEIMITTEL GMBH
Health Canada status: CANCELLED POST MARKET
What is XELODA?
XELODA 500 MG contains CAPECITABINE : 500 MG. It is listed in the Health Canada Drug Product Database under DIN 02238454, held by CHEPLAPHARM ARZNEIMITTEL GMBH, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 07-Dec-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is XELODA used for?
Adjuvant stage III colon cancer; first-line metastatic colorectal cancer; metastatic colorectal cancer with oxaliplatin; advanced/metastatic breast cancer (monotherapy or with docetaxel).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02238454 |
|---|---|
| Brand name | XELODA |
| Generic / active ingredient | CAPECITABINE : 500 MG |
| Manufacturer | CHEPLAPHARM ARZNEIMITTEL GMBH |
| Strength | 500 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | L01BC06 CAPECITABINE |
| AHFS class | 10:00.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 07-Dec-2022 |
| Original market date | 1998-09-10 00:00:00 |
How is it administered?
Standard dose: 1250 mg/m2 twice daily for 14 days, then 7 days rest. Tablets must be swallowed whole with water within 30 minutes after a meal. Do not crush or cut.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text (standard reference to 15-30°C usually applies but not in snippet).
How is it supplied?
150 mg: HDPE bottles or blister packs of 60. 500 mg: HDPE bottles or blister packs of 120.
Contraindications
Hypersensitivity to capecitabine or 5-fluorouracil; severe renal impairment (CrCl <30 mL/min); complete absence of DPD activity; concomitant administration with sorivudine or brivudine.
Warnings and precautions
Serious: Fatal dehydration/renal failure; cardiotoxicity (sudden death); severe skin reactions (SJS/TEN); DPD deficiency toxicity; altered coagulation with anticoagulants.
Is CAPECITABINE in shortage in Canada?
A Canadian shortage report is on file for this molecule: Anticipated — reported by SANIS HEALTH INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code L01BC06 CAPECITABINE. 11 of 20 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| ACH-CAPECITABINE | 150 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02426757 |
| ACH-CAPECITABINE | 500 MG | TABLET | ACCORD HEALTHCARE INC | MARKETED | DIN 02426765 |
| CAPECITABINE | 150 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02514982 |
| CAPECITABINE | 150 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02519879 |
| CAPECITABINE | 500 MG | TABLET | SANIS HEALTH INC | MARKETED | DIN 02514990 |
| CAPECITABINE | 500 MG | TABLET | JAMP PHARMA CORPORATION | MARKETED | DIN 02519887 |
| MINT-CAPECITABINE | 500 MG | TABLET | MINT PHARMACEUTICALS INC | MARKETED | DIN 02508028 |
| SANDOZ CAPECITABINE | 150 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02421917 |
| SANDOZ CAPECITABINE | 500 MG | TABLET | SANDOZ CANADA INCORPORATED | MARKETED | DIN 02421925 |
| TARO-CAPECITABINE | 150 MG | TABLET | TARO PHARMACEUTICALS INC | MARKETED | DIN 02457490 |
Who else supplies CAPECITABINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CAPECITABINE appears in 765 registered pack listings across 13 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.